|
Apr 11
|
Incyte to Report First Quarter Financial Results
|
|
Apr 6
|
Biotech Executive Who Bet on Rival’s Stock Committed Insider Trading, Jury Says
|
|
Apr 1
|
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
|
|
Mar 31
|
12 Best S&P 500 Stocks To Buy According to Analysts
|
|
Mar 29
|
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 27
|
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
|
|
Mar 26
|
SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive
|
|
Mar 17
|
30 Biggest Biotechnology Companies in the World
|
|
Mar 14
|
Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?
|
|
Mar 12
|
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
|
|
Mar 11
|
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
|
|
Mar 10
|
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
|
|
Mar 10
|
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
|
|
Mar 7
|
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
|
|
Mar 4
|
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
|
|
Feb 28
|
Q4 2023 Syndax Pharmaceuticals Inc Earnings Call
|
|
Feb 27
|
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
|
|
Jan 15
|
IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?
|
|
Jan 8
|
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Jan 6
|
EVP & Chief Medical Officer Steven Stein Sells Shares of Incyte Corp (INCY)
|